3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Triple Negative Breast Neoplasms
2
Neuroblastoma
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Ganglioneuroblastoma
2
Unilateral Breast Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
sargramostim
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled